权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Growth Inhibition Induced by Mifepristone in Ovarian Cancer

米非司酮引起的卵巢癌生长抑制

基本信息

批准号：
7264928
负责人：
Carlos Marcelo Telleria
金额：
$ 13.63万
依托单位：
UNIVERSITY OF SOUTH DAKOTA
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-09-18 至 2010-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7264928
关键词：
Adverse effects Affinity Agonist Animals Antineoplastic Agents Binding Breast Cancer Cell Cancer cell line Caring Cause of Death Cell Cycle Cell Death Cell Line Cell Proliferation Cell Survival Cell membrane Cells Chronic Disease Cisplatin Clinic Clinical Research Combined Modality Therapy Cyclin-Dependent Kinase Inhibitor Cytostatics Cytotoxic Chemotherapy Cytotoxic agent DNA Synthesis Inhibition Data Development Diagnosis Disease Dissection Dose Early Diagnosis Effectiveness Endocrine Epigenetic Process Epithelial Epithelial ovarian cancer Epithelium Evaluation Event Experimental Models Failure Feasibility Studies Female Genital Diseases Gene Expression Genetic Genetic Transcription Glucocorticoid Receptor Goals Growth Growth Inhibitors Health Hormonal Human Immunocompromised Host Immunoprecipitation In Vitro Injection of therapeutic agent Investigation Malignant Female Reproductive System Neoplasm Malignant Neoplasms Malignant neoplasm of ovary Measures Mediating Messenger RNA Mifepristone Molecular Molecular Target Multiple Pregnancy Mus Mutation Nuclear Receptors Nude Mice Operative Surgical Procedures Ovarian Patients Pharmaceutical Preparations Phase Phase Transition Physiologic pulse Physiological Platinum Premalignant Prevention Progesterone Progesterone Receptors Progestins Protein Isoforms Pulse taking RU-486 Recurrence Relative (related person)Reporter Genes Research Personnel Research Proposals Resistance Reverse Transcriptase Polymerase Chain Reaction Risk Role Staging Standards of Weights and Measures Steroids Surface Synthetic Progestogens Testing Therapeutic Therapeutic Agents Time Up-Regulation Western Blotting Woman Work Xenograft procedure base cancer cell carcinogenesis cell growth chemotherapeutic agent chemotherapy cytotoxic cytotoxicity design hormone therapy human CDK2 protein immunosuppressed improved in vitro Model in vivo insight killings neoplastic novel strategies novel therapeutics outcome forecast pre-clinical prevent progesterone receptor B programs receptor research study success synergism tumor tumor growth

项目摘要

DESCRIPTION (provided by applicant): The overall goal of this application is to study the feasibility of using the prototypical progesterone receptor modulator mifepristone, also known as "RU486," for ovarian cancer therapeutics. Ovarian cancer is the leading cause of death in women from gynecologic diseases, in part because of the difficulty in performing early diagnosis, and also due to the lack of successful treatment strategies. Treatment for ovarian cancer generally involves cytoreductive surgery followed by platinum-based chemotherapy, yet the major barrier that this treatment encounters is the development of chemoresistance, which leads to therapeutic failure. It is therefore clear that new therapeutic options for patients with advanced disease are desperately needed. Our preliminary data have demonstrated that mifepristone not only is a cytostatic agent for ovarian cancer cells, but also enhances the cytotoxicity of the standard chemotherapeutic agent cisplatin. These results led to the hypothesis that mifepristone can be exploited therapeutically in two manners: first as a cytostatic agent blocking the repopulation of cells that had survived chemotherapy; and second, enhancing chemotherapy-induced lethality. Specific aim 1 will identify the underlying molecular mechanism of the cytostatic effect of mifepristone in cultured ovarian cancer cells, and will test the efficacy of the compound in an in vivo setting using immunocompromised mice. Specific aim 2, using ovarian cancer cell lines of similar genetic backgrounds but carrying different sensitivities to cisplatin, will define whether mifepristone prevents repopulation of cancer cells in between rounds of cisplatin chemotherapy and the mechanism whereby it enhances cisplatin-mediated lethality. Results from this investigation have the potential for a major impact on human health because combination of mifepristone with standard cytotoxic chemotherapy would allow a reduction in the effective dose of cytotoxic drugs leading to reduced toxic side effects, lower chemoresistance and longer survival. At present there is no hormonal therapy approved for the treatment of any type of ovarian malignancy, yet the rationale of our preliminary results suggest that mifepristone is a promising hormonal therapeutic agent to be added to the list of anti-epithelial ovarian cancer drugs with the final goal of converting this lethal cancer into a treatable chronic disease.

描述(申请人提供)：本申请的总体目标是研究将典型的孕激素受体调节剂米非司酮(也称为“RU486”)用于卵巢癌治疗的可行性。卵巢癌是妇女死于妇科疾病的主要原因，部分原因是很难进行早期诊断，也因为缺乏成功的治疗策略。卵巢癌的治疗通常包括细胞减灭术和以铂为基础的化疗，然而这种治疗遇到的主要障碍是化疗耐药性的产生，这导致治疗失败。因此，很明显，迫切需要为晚期疾病患者提供新的治疗方案。我们的初步数据表明，米非司酮不仅对卵巢癌细胞具有细胞抑制作用，而且还能增强标准化疗药物顺铂的细胞毒性。这些结果导致了这样的假设，即米非司酮可以通过两种方式用于治疗：第一，作为一种细胞抑制剂，阻止化疗后存活的细胞重新繁殖；第二，增强化疗诱导的致命性。具体目标1将确定米非司酮对培养的卵巢癌细胞的细胞抑制作用的潜在分子机制，并将在体内使用免疫功能低下的小鼠测试该化合物的疗效。具体目的2，使用遗传背景相似但对顺铂敏感性不同的卵巢癌细胞株，将确定米非司酮是否可以防止顺铂化疗期间癌细胞的再繁殖，以及它增强顺铂介导的致命性的机制。这项研究的结果有可能对人类健康产生重大影响，因为米非司酮与标准的细胞毒性化疗相结合，可以减少细胞毒性药物的有效剂量，从而减少毒副作用，降低化疗耐药性，延长生存期。目前还没有激素疗法被批准用于治疗任何类型的卵巢恶性肿瘤，但我们初步结果的基本原理表明，米非司酮是一种很有前途的激素治疗剂，有望被添加到抗上皮性卵巢癌药物清单中，最终目标是将这种致命的癌症转变为可治疗的慢性疾病。